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Antiplatelet therapy following peripheral arterial endovascular intervention lacks high quality
evidence to guide practice. The aim of this study was to assess the effect of three months of
dual antiplatelet therapy on amputation-free survival following peripheral arterial endovascu-
lar intervention in patients with chronic limb threatening ischemia.
Methods
A retrospective review of symptomatic patients undergoing primary peripheral arterial endo-
vascular intervention over a seven-year period was performed. The primary outcome mea-
sure was amputation-free survival. A sample size calculation based on previous cohort
studies suggested that 629 limbs would be required to show a difference between single
and dual therapy. Kaplan-Meier estimates and multivariate logistic regression analysis of
recorded baseline characteristics was performed to determine predictors of amputation-free
survival. Dual antiplatelet therapy was routinely given for 3 months.
Results
754 limbs were treated with primary angioplasty and/or stenting over a 7-year period, 508 of
these for chronic limb threatening ischemia. There was no difference in unadjusted amputa-
tion-free survival between patients with chronic limb threatening ischaemia taking single vs.
dual antiplatelet therapy (69% vs. 74% respectively Log rank Chi2 = 0.1, p = .72). After
adjusting for confounders, at 1 year there was also no significant difference in amputation-
free survival between patients taking single vs. dual antiplatelet therapy [OR 0.8, 95% CI
0.5–1.2, p = .3]. There was no difference in rates of major bleeding between single and dual
antiplatelet therapy.
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Conclusions
There was no clear evidence of reduced amputation-free survival in patients with chronic
limb threatening ischemia undergoing peripheral arterial endovascular intervention being
treated with dual antiplatelet therapy for 3 months. This is at odds with other retrospective
case series and highlights the limitations in basing clinical practice on such data. There is a
need for an adequately powered, independent randomised trial to definitively answer the
question.
Introduction
Antiplatelet therapy following peripheral arterial endovascular intervention lacks high-quality
evidence to guide practice [1]. This is surprising given the large number of randomised trials
to guide antiplatelet practice in other areas of treatment for peripheral arterial disease, and
causes conflict between recommendations in guidelines [2,3]. It has also resulted in a variation
in clinical practice between clinicians, centers and countries [4].
There is one small randomised trial examining single vs. dual antiplatelet therapy after
endovascular intervention [5,6]. This lacked the power to compare clinically relevant out-
comes such as amputation rates or amputation-free survival. The trial recruited forty patients
in each arm and at 12 months there was no statistically significant difference between target
lesion revascularisation in the dual antiplatelet arm (Aspirin and Clopidogrel) over Aspirin
single therapy.
There is case-series evidence to support a benefit of dual antiplatelet therapy in patients
undergoing peripheral endovascular intervention [7–9]. However, these series included a het-
erogenous patient mix including patients undergoing intervention for claudication and
patients undergoing secondary intervention. The most important group of patients undergo-
ing intervention for peripheral arterial disease are those with chronic limb threatening ischae-
mia who are at the highest risk of amputation or death if treatment fails [10]. This group is
vastly under-represented in previous case series. Moreover, long (over 6 months) durations of
antiplatelet therapy was used in these studies, however clinical practice varies worldwide and
many UK units, including ours, used short (less than 6 months) courses [1,11].
The aim of this paper was to examine the clinically relevant differences between single and
dual antiplatelet therapy following peripheral arterial intervention for chronic limb threaten-
ing ischaemia in a way which minimises previous case series’ flaws: a powered, clearly specified
cohort with statistically valid follow up criteria and adjusted outcome reporting.
Methods
Study design
This was a retrospective cohort study of patients undergoing primary lower limb peripheral
arterial endovascular intervention for claudication or chronic limb threatening ischaemia. The
study was approved by the Aneurin Bevan University Health Board Research and Develop-
ment department (ABUHB R&D reference number: SA/710/16) and registered on ANZCTR.
The research and development approval waives the requirement for informed consent which
is in place for all approved studies using the clinical workstation browser. The study is reported
in line with the STROBE statement [12].
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Study patients
Patients undergoing primary lower limb arterial endovascular intervention at the Royal Gwent
Hospital, Newport between January 2010 and January 2017 were screened for inclusion. The
Health Board’s electronic clinical workstation browser was used to collect anonymized data;
all data were anonymized for collection and analysis. Clinical workstation is linked to the office
for national statistics in the UK for mortality reporting.
Pre-procedural data associated with poor amputation-free survival [13,14] was collected on
each patient including baseline blood tests (white cell count, haemoglobin, platelet count, urea,
creatinine, eGFR and albumin), co-morbidities (ischaemic heart disease, diabetes, hyperten-
sion, congestive cardiac failure, chronic obstructive airways disease and cerebrovascular acci-
dent), smoking status, angiotensin converting enzyme inhibitor or angiotensin II receptor
blocker and statin usage. Data on anatomical location of the lesion and endovascular treatment
device ((balloon—plain or drug eluting; stent—bare metal, drug eluting or covered) was also
collected.
All patients were discussed by a multidisciplinary team before intervention. After discharge
following intervention patients were routinely followed up at 6 weeks in an outpatient clinic.
Patients with tissue loss were followed up in a wound healing service until the point of healing
(defined as full epithelialization). Patients undergoing stent implantation were followed up
with duplex surveillance at 3, 6, 9 and 12 months. Recurrent stenoses >75% were discussed by
a multidisciplinary team and offered repeat intervention if clinically appropriate. The study
end date was 30/09/2018, however, survival and re-intervention times were defined up to last
known date of follow-up. The follow-up period was measured relative to the declared study
end date. A follow-up index was calculated for each patient. This is defined as the ratio
between the investigated follow-up period and the theoretically possible follow-up period to
the pre-specified study end date [15]. The international classification of diseases was used for
disease definitions, apart from ischaemic heart disease which includes angina and myocardial
infarction definitions [16].
Inclusion criteria
• Primary (first) lower limb intervention for atherosclerotic peripheral arterial disease
• Angioplasty or stenting with any device
• Angioplasty or stenting of the distal infra-renal aorta with common iliac disease; common or
external iliac arteries; superficial femoral artery; popliteal artery; tibio-peroneal trunk; ante-
rior or posterior tibial artery; peroneal artery or any pedal artery.
Exclusion criteria
• Patients undergoing treatment for aneurysmal disease or for a complication of treatment of
aneurysmal disease
• Secondary or endovascular re-intervention to the same limb
• Treatment proximal to the infra-renal aorta; mesenteric or renal vessels; upper limb or head
and neck vessels
• Hybrid revascularization procedures
PLOS ONE Single vs. dual antiplatelet therapy after peripheral angioplasty
PLOS ONE | https://doi.org/10.1371/journal.pone.0234271 June 11, 2020 3 / 13
• Patients undergoing intra-arterial embolectomy, thrombectomy or thrombolysis, other than
those where this was commenced immediately following primary angioplasty or stenting in
order to treat a complication
• Venous procedures (e.g. deep venous stenting)
• Angioplasty or stenting of arterio-venous fistulas or arterio-venous malformations
• Patients receiving therapeutic anticoagulation
• Patients receiving dual antiplatelet therapy for another cause prior to peripheral endovascu-
lar intervention
• Patients receiving no anti-platelet therapy at the time of discharge
Endpoints
Primary endpoint. Amputation-free survival (composite of mortality plus major lower
limb amputation defined as above ankle) [2]. We have performed patient focus group work as
part of the run up for a randomised trial of single vs. dual antiplatelet therapy which confirmed
this to be the most important patient centered outcome after treatment for chronic limb
threatening ischaemia. It is also a widely accepted effectiveness outcome in chronic limb
threatening ischaemia used in several major randomised trials [2].
Primary safety endpoint. Major bleeding (using the International Society on Thrombosis
and Haemostasis definition) [17].
Secondary endpoints. Survival, limb salvage, target lesion revascularisation, trends in
dual antiplatelet therapy prescription with time.
Antiplatelet therapy
Antiplatelet therapy was prescribed by the consultant vascular surgeon or interventional radi-
ologist looking after the patient. Choice of antiplatelet therapy was at the discretion of the
attending surgeon/radiologist. There were no specific criteria for using single or dual antiplate-
let therapy, it was dictated by the practice of the person performing the procedure. The hospi-
tal prescription would last for 4–6 weeks and a summary would be given to the patient and GP
for continuation. Dual antiplatelet therapy was continued for a period of 3 months after inter-
vention and long term single antiplatelet therapy was given after this.
Sample size calculation
In the previously published case series the rate of dual antiplatelet therapy varied: 31% in a
Swedish registry study [7], 55% in a single centre study from America [8] and 69% in an Amer-
ican registry study [9]. The benefits of dual therapy also varied between the studies; with a haz-
ard ratio [HR 0.54] in favour of dual antiplatelet therapy in the Armstrong et al single centre
study, HR 0.89 for mortality in the American registry, and HR 0.72 and HR 0.77 for survival
and amputation respectively in the Swedish registry. The variability in previous similar case
series made it difficult to estimate the prevalence and treatment effect of dual therapy in our
cohort a-priori.
Patients with chronic limb threatening ischaemia could not be analysed separately for a
sample size calculation from the cohort studies above. Therefore a total sample size calculation
was performed for all patients undergoing intervention presuming a similar case mix and the
chronic limb threatening ischaemia patients were analysed alone in our study. Sample size
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calculations were based on a 40% prevalence of dual antiplatelet therapy and a hazard ratio
0.65 to estimate the treatment effect of dual therapy (our primary outcome is amputation-free
survival) in our cohort. With mortality rates between 20%-30% and amputation rates 8%-15%
in the previous three case series, the estimated event rate was 28%. Therefore, using standard
size sample size calculation [18], we estimated that six hundred and twenty nine patients
would be required to have 80% power to show a difference comparable to the published litera-
ture at the 5% level with a median follow-up of 36 months. Based on previous audit we knew
that 120–140 procedures were performed annually, so on the assumption that we were likely
to exclude approximately 25% of patients due to treatment of patients without chronic limb
threatening ischaemia or who were on anticoagulation, we estimated that seven years (the
period during which electronic records were available) should be enough to achieve adequate
power to address the study question.
Statistical analysis
All data was anonymized prior to analysis. The data were cleaned by first resolving transcrip-
tional discrepancies and clinical conflicts. Aberrant and extreme values were removed or
transformed if the cause was inconsistent measurement units. All variables missing more than
15% of data were excluded from analyses. The sample median was substituted for missing con-
tinuous variables and the mode for missing categorical variables.
For descriptive data with a normal distribution the mean±standard deviation (SD) was
specified and comparisons were performed using a two-sided student’s t-test. For data with
non-normal distribution the median and interquartile range were given and comparisons
made using the Mann Whitney U test. For categorical variables comparisons were performed
using the Fisher’s exact test. Unadjusted event free survival was estimated using the Kaplan-
Meier method and between group difference assessed using the log-rank test [19] Potential
confounders of amputation-free survival were adjusted for: Baseline white cell count, haemo-
globin, platelet count, urea, creatinine, eGFR, albumin, ischaemic heart disease, hypertension,
diabetes mellitus, cerebrovascular event, congestive cardiac failure, chronic obstructive airways
disease, statin, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker
usage, anatomical location of the lesion and treating endovascular device (balloon—plain or
drug eluting; stent—bare metal, drug eluting or covered). Confounder correction using Cox
Proportional Hazards method was undertaken with stepwise selection of confounders through
minimization of the Akaike Information Criterion to reduce model over-fitting. Scaled
Schoenfeld residuals were analysed to assess for violation of the proportional hazards assump-
tion [20].
The primary endpoint was also examined at 1-year post intervention as trials in cardiology
suggest the greatest benefit to this time period [21], and to minimize error due to attrition. We
used logistic regression analysis and odds ratios to analyze risk factors associated with poor
amputation-free survival. Multivariate logistic regression was used to adjust for confounders
(baseline white cell count, haemoglobin, platelet count, urea, creatinine, eGFR, albumin,
ischaemic heart disease, hypertension, diabetes mellitus, cerebrovascular event, congestive car-
diac failure, chronic obstructive airways disease, statin, angiotensin converting enzyme inhibi-
tor or angiotensin II receptor blocker usage, anatomical location of the lesion and treating
endovascular device), with stepwise selection of significant confounding variables by minimiz-
ing the Akaike information criterion (AIC) [22]. A further sensitivity analysis was performed
to assess the effect of drug eluting devices. Linear regression was carried out to examine trends
of antiplatelet prescription with time. All statistical analysis was performed within the R
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statistical programming environment version 3.5.1 and for all tests a p value of< .05 was con-
sidered significant.
Results
Patient demographics and interventions
Nine hundred and twenty-seven patients were screened for inclusion in the study (Fig 1). Six
hundred and twenty-five patients and seven hundred and fifty-four limbs met the inclusion/
exclusion criteria were treated with primary angioplasty or stenting over the seven-year period.
Five hundred and eight of these were performed in patients with chronic limb threatening
ischaemia. The mean age of the entire cohort was 69.8±10.9 years; three hundred and ninety-
six (63%) patients were male. The median follow-up time was 29 (8–33) months, with a mean
follow-up index of 0.94±0.1. There were 244 deaths during the study period (208 patients with
chronic limb threatening ischaemia and 36 with intermittent claudication). Only two variables
were excluded because of>15% missing data: smoking and the Wound Ischaemia and Foot
infection score.
Fig 1. Patient cohort development.
https://doi.org/10.1371/journal.pone.0234271.g001
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Amputation-free survival in patients with chronic limb threatening
ischaemia
There were differences in single and dual therapy by anatomical location and endovascular
treatment device used (Table 1).
Overall unadjusted amputation-free survival for patients with chronic limb threatening
ischaemia was 79% at 6 months, 71% at one year, 63% at 2 years and 55% at 3 years. There was
no difference in unadjusted amputation-free survival (Log rank Chi2 = 0.1, p = .72 Fig 2).
On adjusting for confounders (baseline white cell count, haemoglobin, platelet count, urea,
creatinine, eGFR, albumin, ischaemic heart disease, hypertension, diabetes mellitus, cerebro-
vascular event, congestive cardiac failure, chronic obstructive airways disease, statin, angioten-
sin converting enzyme inhibitor or angiotensin II receptor blocker usage, anatomical location
of the lesion and endovascular device, S1 Table), amputation-free survival was not associated
with choice of antiplatelet therapy [HR 0.94, 95% CI 0.7–1.3, p = .7].
The cardiology literature suggests benefit to one year from a course of dual antiplatelet ther-
apy.11 When truncating follow-up at 1 year in this cohort there was also no significant differ-
ence in amputation-free survival between patients taking single or dual antiplatelet therapy
[OR 0.8, 95% CI 0.5–1.2, p = .3] after adjusting for the following confounding variables: base-
line white cell count, haemoglobin, platelet count, urea, creatinine, eGFR, albumin, ischaemic
heart disease, hypertension, diabetes mellitus, cerebrovascular event, congestive cardiac failure,
chronic obstructive airways disease, statin, angiotensin converting enzyme inhibitor or angio-
tensin II receptor blocker usage, anatomical location of the lesion and endovascular device (S1
Table).
Major bleeding
There was no statistically significant difference in major bleeding between the dual antiplatelet
therapy (n = 8) and single therapy group (n = 26) of patients (p = 1). There was no statistically
significant difference in major bleeding between aspirin and clopidogrel in the single therapy
group (21/437 patients taking aspirin vs 5/145 patients taking clopidogrel, p = 0.6). These
trends were the same for chronic limb threatening ischaemia patients alone (p = .82).
Secondary endpoints in patients with chronic limb threatening ischaemia
Survival was no different between patients receiving single and dual antiplatelet therapy (Log
Rank Chi2 = 0, p = .9). This was also the case after adjusting for confounders (baseline white
cell count, haemoglobin, platelet count, urea, creatinine, eGFR, albumin, ischaemic heart dis-
ease, hypertension, diabetes mellitus, cerebrovascular event, congestive cardiac failure, chronic
obstructive airways disease, statin, angiotensin converting enzyme inhibitor or angiotensin II
receptor blocker usage, anatomical location of the lesion and endovascular device, S1 Table;
HR 1.0, 95% CI 0.7–1.4, p = .9).
There were eighty-five post intervention major lower limb amputations: 70 (17.6%) in the
single therapy group and 15 (12.6%) in the dual therapy group. There was no difference in
limb salvage rates between patients receiving single or dual antiplatelet therapy (Log Rank
Chi2 = 1.7, p = .2). This was also the case after adjusting for confounders (baseline white cell
count, haemoglobin, platelet count, urea, creatinine, eGFR, albumin, ischaemic heart disease,
hypertension, diabetes mellitus, cerebrovascular event, congestive cardiac failure, chronic
obstructive airways disease, statin and angiotensin converting enzyme inhibitor or angiotensin
II receptor blocker usage, anatomical location of the lesion and endovascular device, S1 Table;
HR 0.6, 95% CI 0.3–1.1, p = .1).
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Table 1. Baseline characteristics of patients with chronic limb threatening ischaemia.
Single therapy n = 389 Dual Therapy n = 119 P
Aspirin (n) 318 Aspirin + Clopidogrel 113 -
Clopidogrel (n) 71 Aspirin + Prasugrel 5 -
Aspirin + Ticagrelor 1 -
Concurrent statin n(%) 285(73) 92(77) 0.29
Concurrent ACEi n(%) 200(51) 59(50) 0.92
Co-morbidities
IHD n(%)� 173((44) 51(43) 0.92
Diabetes n(%) 222(57) 71(60) 0.53
Hypertension n(%) 303(78) 97(82) 0.26
CVE n(%)�� 55(14) 25(21) 0.06
COPD n(%) 66(17) 22(18) 0.68
CCF n(%) 83(21) 30(25) 0.32
Blood results (Median(IQR))
Haemoglobin (g/L) 122 (109–138) 120 (108–136) 0.18
Platelets (109/L) 291 (236–365) 293 (229–364) 0.16
WCC (109/L) 9.4 (7.6–11.4) 9.4 (7.6–11.4) 0.27
Urea (mmol/L) 6.0 (4.4–8.1) 5.9 (4.4–8.3) 0.22
Creatinine (mmol/L) 79 (67–106) 79 (68–108) 0.94
eGFR 76 (57–98) 77 (56–99) 0.4
Albumin (g/L) 33 (28–37) 32 (27–36) 0.21
Minor amputations (n) 57 19 0.66
Major amputations
Transtibial (n) 45 9 0.24
Transfemoral (n) 25 6 0.6
Major bleeding events (n) 18 6 0.82
Anatomical location
Aorto-iliac 102 57 <0.00001
Femoro-popliteala 126 41 0.74
Below the kneeb 88 9 0.000245
Iliac + Fem-pop 6 1 1
Iliac + BTK 1 0 1
Fem-pop + BTK 65 11 0.06
Endovascular device
Balloon angioplasty 261 50 <0.00001
Drug eluting balloon 98 55 0.000012
Bare metal stent 5 2 0.67
Drug eluting stent 5 6 0.013951
Covered stent 1 4 0.003138
IHD = Ischaemic Heart Disease; CVE = Cerebrovascular Event; COPD = Chronic Obstructive Pulmonary Disease; CCF = Congestive Cardiac Failure; WCC = White
Cell Count
� Ischaemic heart disease was defined as angina and/or previous myocardial infarction.
�� CVE includes both stroke and transient ischaemic attack
a Femoro-popliteal (fem-pop) ends at the level of P2
b Below the knee (BTK) starts at P3
https://doi.org/10.1371/journal.pone.0234271.t001
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Target lesion revascularisation rates were no different between the groups. Re-intervention
was performed in 152 (29%) limbs with 120 (31%) on single therapy and 32 (27%) on dual
antiplatelet therapy post primary intervention (p = .5). The median time to reintervention was
6 (2–18) months.
A change in antiplatelet prescription was noted over time with clinicians prescribing clopi-
dogrel rather than aspirin single therapy and dual antiplatelet therapy more frequently with
Fig 2. Kaplan-Meir curve showing amputation-free survival for patients with chronic limb threatening ischaemia receiving single or dual antiplatelet
therapy following peripheral endovascular intervention. The Y axis shows probability of survival and the X axis shows time in months.
https://doi.org/10.1371/journal.pone.0234271.g002
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time (Fig 3). There was an increasing trend in the proportion of patients being discharged on
dual antiplatelet therapy increased from 2% in 2010 to 26% in 2016 (p = .0003).
Discussion
There was no statistically significant difference in amputation-free survival or major bleeding
events between patients on single or dual antiplatelet therapy after lower limb endovascular
intervention for chronic limb threatening ischaemia.
The main finding is interesting for a number of reasons. Although the study had appropri-
ate statistical power to detect differences similar to the previously published literature, the case
mix is different with fewer diabetics in our study than one of the large cohort studies used for
the calculation [7]. As event rates were higher in the diabetic cohort in this study it may be no
effect is shown in our data as a result. There were difference in use of single and dual therapy
by both anatomical location and endovascular device used. This is in keeping with a previous
international survey of practice [4] and would potentially confound previous unadjusted
studies.
Three months of dual therapy was used in our cohort as opposed to longer courses in previ-
ous cohorts [8,9]. In trials comparing the duration of dual antiplatelet therapy after percutane-
ous coronary intervention there are debates over the optimal length of treatment because of
the balance of risk and benefit [11]. Durations of antiplatelet therapy longer than twelve
months after percutaneous coronary stenting cause harm as a result of increased major bleed-
ing rates which means most guidelines do not recommend courses over six to twelve months
[23–26]. Conversely, the STOPDAPT-2 study showed benefit for only a 1 month course of
dual therapy [27]. As this is undefined following percutaneous lower limb intervention it may
Fig 3. Change in antiplatelet prescribing post peripheral endovascular intervention over time. Dual antiplatelet therapy (R2 = 0.94, p = .0003)
Clopidogrel (R2 = 0.41, p = .12). Y axis shows number of cases and X axis shows year of prescription.
https://doi.org/10.1371/journal.pone.0234271.g003
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be the case that six or twelve months rather than three months of dual therapy would show a
difference between the groups at one year.
Major bleeding events showed no difference between the groups. The overall rate of major
bleeding was 54 per 1000 patients which is similar to that reported in previous randomised tri-
als [1]. The sample size in this study is therefore too small to detect a significant difference, but
it is reassuring that there is no large discrepancy.
The trend in increasing use of dual therapy over time is in keeping with previous work
showing this to be the case [4]. It may be that clinical practice is being extrapolated from cardi-
ology or from randomised trials of newer technologies such as drug eluting stents, where dual
therapy was often specified in the protocol with no justification [28]. Either way there is a
potential that this causes more harm than good while we do not fully understand the benefit
for amputation-free survival.
This analysis has a number of limitations. Retrospective studies are limited by the type and
quality of the data collected. Even though a sample size calculation was performed this is not
as powerful for retrospective data as if the study was prospective. It is helpful to guide the num-
ber of patients included in the study but cannot be seen as definitive. There is still the possibil-
ity of type 2 error in any of the comparison, especially as the groups become smaller. Smoking
status is associated with increasing atherosclerotic burden as well as increased risk of major
adverse cardiovascular events [29]. There was lack of sufficient data on the smoking status of
patients in this cohort so we were unable to account for the effect of confounding due to this
factor in our analysis. A lack of strict antiplatelet protocol means that longer or shorter dura-
tions may have been taken by patients and no compliance checks were made.
The study also has several major strengths for a retrospective cohort. A sample size calcula-
tion was performed based on previous publications in this area and there was sufficient statisti-
cal power to detect differences similar to those seen in previous published studies. We focused
on patient centered clinical endpoints in patients with chronic limb threatening ischaemia,
who benefit most from these interventions. Inclusion/exclusion and endpoint criteria were
prespecified and adhered to and follow-up reporting was robust, as demonstrated by the mean
follow-up index of 0.94.
This research alone is not high enough quality to make recommendations for practice, nor
is any other cohort study or previously published randomized trial in the area [5–9]. The con-
flicting results make it clear that an adequately powered randomised trial in this area is
required to make practice recommendations.
Conclusion
There was no evidence of improved amputation-free survival in patients with chronic limb
threatening ischaemia undergoing peripheral arterial endovascular intervention being treated
with 3 months of dual antiplatelet therapy over those on a single agent. This is at odds with
other retrospective case series and highlights the dangers in basing clinical practice on such
data. There is a need for a high-quality randomised trial to definitively answer the question of
whether dual antiplatelet therapy is of benefit after peripheral endovascular intervention.
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